Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Evolving Paradigm of Gastrointestinal Cancers
November 10th 2017John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the evolving paradigm of gastrointestinal cancers.
Watch
Expected Findings of the SWOG S1505 Trial in Pancreatic Cancer
October 27th 2017Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Watch
DAAs Are Not Associated With Increased HCC Recurrence Risk, Study Finds
October 27th 2017In a presentation during the 2017 International Liver Cancer Association Annual Conference, Amit G. Singal, MD, discussed data surrounding the use of direct acting antivirals, a novel and completely oral hepatitis C therapy, which has been associated with a high response rate.
Read More
FGFR4 Inhibitor Demonstrates Promising Activity in HCC Subgroup
October 27th 2017An overall response rate of 16% was demonstrated in patients with FGF 19 immunohistochemistry-positive hepatocellular carcinoma treated with BLU-554, which was higher than the response rates of 10% or less that are seen with the currently approved HCC treatments.
Read More
Predictive and Prognostic Biomarkers Sought in HCC
October 27th 2017Researchers are seeking prognostic biomarkers for response to treatment with adjuvant sorafenib (Nexavar) in patients with hepatocellular carcinoma, according to a presentation during the 2017 International Liver Cancer Association Annual Conference in Seoul, South Korea.
Read More
Phase III Trial Needed to Confirm Clinical Benefit of Cabozantinib in Carcinoid and Pancreatic NETs
October 20th 2017Encouraging results are being seen following the administration of cabozantinib (Cabometyx) in patients with carcinoid and pancreatic neuroendocrine tumors. Clinical benefit of the drug has been exhibited in patients enrolled in a prospective phase II trial, which was initiated in July 2012; however, a randomized phase III trial will be necessary for confirmation.
Read More
NANETS Chair Explains How Symposium Addresses the Multidisciplinary Needs of Treating NETs
October 19th 2017David Metz, MD, chair of the North American Neuroendocrine Tumor Society, discusses the focus on multidisciplinary care and exciting areas of research being presented during the 10th Annual NANETS Symposium.
Read More
NETs Expert Looking Forward to New Research Updates, Networking at Upcoming NANETS Symposium
October 19th 2017As an experienced medical oncologist and clinical researcher specializing in the treatment of gastrointestinal tumors, Pamela Kunz, MD, says the upcoming 2017 North American Neuroendocrine Tumor Society (NANETS) Annual Symposium offers her a chance to not only expand her own knowledge of neuroendocrine tumor research, but also allows her to share her past experience with professionals just starting out in the field.
Read More
NANETS to Bring All Specialties in the NETs Community Together for 10th Annual Symposium
October 19th 2017The 2017 North American Neuroendocrine Tumor Society (NANETS) Annual Symposium is kicking off tomorrow, October 19, in Philadelphia with a 3-day lineup of presentations sure to leave professionals in the neuroendocrine community with a better understanding of ongoing neuroendocrine tumor research efforts, a look at what is on the horizon, and an abundance of networking opportunities with a variety of specialists throughout their field.
Read More
Morse Details Treatment Considerations in 2 Colorectal Cancer Case Scenarios
October 10th 2017Michael A. Morse, MD, recently discussed treatment decisions centered around the care of patients with metastatic colorectal cancer. Morse, professor of Medicine, Duke Cancer Institute, explained his treatment decisions in 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Alexander Named Chief Surgical Officer at Rutgers Cancer Institute
October 5th 2017Internationally recognized surgeon H. Richard Alexander, MD, FACS, has been appointed as the new chief surgical officer at Rutgers Cancer Institute of New Jersey. He will also be a professor of surgery in the Division of Surgical Oncology at the Rutgers Robert Wood Johnson Medical School and a part of the Gastrointestinal Oncology Program at the cancer institute when his position begins this fall, according to a press release from Rutgers Cancer Institute of New Jersey.
Read More
Lenvatinib Application for Advanced HCC Accepted by FDA
September 27th 2017A supplemental new drug application for lenvatinib as a frontline systemic treatment for patients with advanced hepatocellular carcinoma has been accepted by the FDA, acccording to a statement from Eisai, the company developing the therapy.
Read More
Diaz Discusses Phase III Trial of Pembrolizumab in Frontline MSI-H Colorectal Cancer
September 27th 2017In the phase III KEYNOTE-177 trial, investigators are hoping to show that frontline treatment with the PD-1 inhibitor pembrolizumab (Keytruda) can improve progression-free survival compared with standard-of-care chemotherapy in patients with mismatch repair-deficient or microsatellite instability-high colorectal cancer.
Read More
Expert Discusses Study Exploring Prognostic, Predictive Value of Tumor Location in CRC
September 26th 2017Investigators aimed to evaluate the prognostic value of primary tumor location in patients with fully resected colon cancer, as well as its relationship to microsatellite instability-high (MSI-H), <em>RAS</em>, and <em>BRAF</em> mutational status, in a study presented at this year's World Congress on Gastrointestinal Cancer.
Read More
Improving Outcomes in Pancreatic Cancer With Perioperative mFOLFIRINOX
September 26th 2017Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the need for an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Watch
Pembrolizumab Receives FDA Approval for PD-L1+ Gastric Cancer
September 23rd 2017Based on findings from the phase II KEYNOTE-059 study, pembrolizumab has been granted FDA approval for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.
Read More
Pisters Selected as Next MD Anderson Cancer Center President
September 22nd 2017Peter W. T. Pisters, MD, MHCM, has been chosen as the next president of The University of Texas MD Anderson Cancer Center. Pisters has served as president and CEO of University of Health Network (UHN) of Toronto since 2015.
Read More
BLU-554 Demonstrates Improved Response Rates in HCC
September 21st 2017While currently-approved treatments for HCC are typically associated with responses rates of 10% or less, findings presented at the 11th Annual Conference of the ILCA, BLU-554, a potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), induced an overall response rate of 16% (95% CI, 6-31) in patients with FGF 19 IHC-positive HCC.
Read More
Lenvatinib Continues to be Noninferior to Sorafenib in Liver Cancer, Updated Results Show
September 21st 2017In updated phase III results, lenvatinib continued to be noninferior in overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma, and achieved significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib.
Read More
Finn Shares Insight on Practice-Changing Studies in Liver Cancer
September 20th 2017Multidisciplinary findings across the field of hepatocellular carcinoma will be showcased at the 11th International Liver Cancer Association Annual Conference on September 15 to 17 in Seoul, South Korea. Abstracts already under discussion at this year’s ILCA conference include pivotal research on VGEF inhibitors, immunotherapy regimens, and biomarkers.
Read More
Predictive Biomarkers Not Found in STORM Study for Sorafenib in HCC
September 18th 2017Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib. According to an analysis of the phase III STORM study presented at the 11th International Liver Cancer Association Annual Conference, a predictive biomarker for recurrence was not uncovered.
Read More